Xbrane Biopharma AB (publ) (STO: XBRANE)
Sweden
· Delayed Price · Currency is SEK 0.177
-0.004 (-2.21%)
Dec 4, 2024, 4:40 PM CET
Xbrane Biopharma AB Cash Flow Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -370.56 | -388.17 | -172.51 | -188.38 | -226.03 | -187.99 | Upgrade
|
| Depreciation & Amortization | 23.47 | 21.43 | 16.58 | 12.22 | 5.77 | 6.52 | Upgrade
|
| Other Amortization | - | - | - | - | 0.79 | 0.8 | Upgrade
|
| Stock-Based Compensation | - | - | - | - | 1.29 | 2.09 | Upgrade
|
| Other Operating Activities | 87.08 | 79.22 | -7.25 | -5.04 | -1.61 | 15.3 | Upgrade
|
| Change in Accounts Receivable | -61.2 | -85.13 | 1.7 | -61.09 | -51.33 | -28.29 | Upgrade
|
| Change in Inventory | -104.76 | -56.6 | -50.26 | - | - | - | Upgrade
|
| Change in Accounts Payable | 94.63 | - | - | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | 22.57 | 22.57 | 17.83 | 22.67 | 32.7 | 42.97 | Upgrade
|
| Operating Cash Flow | -308.77 | -406.68 | -193.92 | -219.61 | -238.41 | -148.59 | Upgrade
|
| Capital Expenditures | -0.68 | -6.79 | -11.62 | -27.68 | -3.86 | -1.19 | Upgrade
|
| Sale (Purchase) of Intangibles | -34.45 | -9.98 | -48.51 | -49.67 | - | - | Upgrade
|
| Investing Cash Flow | -35.12 | -16.77 | -60.13 | -77.35 | -3.86 | -1.19 | Upgrade
|
| Long-Term Debt Issued | - | 225 | - | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -34.74 | -8.34 | -7.27 | -3.14 | -2.99 | Upgrade
|
| Total Debt Repaid | -137 | -34.74 | -8.34 | -7.27 | -3.14 | -2.99 | Upgrade
|
| Net Debt Issued (Repaid) | -87 | 190.26 | -8.34 | -7.27 | -3.14 | -2.99 | Upgrade
|
| Issuance of Common Stock | 337.24 | 120.02 | 170.55 | 380.87 | 346.45 | 252.46 | Upgrade
|
| Other Financing Activities | -37.48 | -11.58 | -13.35 | -24.23 | -20.58 | -33.43 | Upgrade
|
| Financing Cash Flow | 212.77 | 298.7 | 148.86 | 349.37 | 322.72 | 216.04 | Upgrade
|
| Foreign Exchange Rate Adjustments | -6.02 | -4.49 | 4.05 | 1.39 | -1.52 | -3.04 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0.45 | 0.64 | -0.05 | -1.76 | - | - | Upgrade
|
| Net Cash Flow | -136.69 | -128.59 | -101.19 | 52.04 | 78.94 | 63.23 | Upgrade
|
| Free Cash Flow | -309.44 | -413.47 | -205.53 | -247.29 | -242.26 | -149.78 | Upgrade
|
| Free Cash Flow Margin | -154.87% | -173.20% | -356.72% | -2309.16% | - | - | Upgrade
|
| Free Cash Flow Per Share | -0.36 | -14.40 | -8.04 | -10.48 | -13.37 | -13.38 | Upgrade
|
| Cash Interest Paid | 7.58 | 7.58 | 2.59 | 2.64 | 0.69 | 1.47 | Upgrade
|
| Levered Free Cash Flow | -195.08 | -244 | -169.78 | -279.72 | -153.39 | -82.25 | Upgrade
|
| Unlevered Free Cash Flow | -164.93 | -232.43 | -168.17 | -278.07 | -152.96 | -81.34 | Upgrade
|
| Change in Net Working Capital | -6.07 | 53.48 | 38.06 | 109.45 | 22.31 | -22.56 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.